{"entity":{"id":"il-yang-pharmaceutical","kind":"company","name":"Il-Yang Pharmaceutical","aka":["Il-Yang Pharm","Ilyang","일양약품"],"tldr":"Il-Yang Pharmaceutical is a South Korea-based pharmaceutical company that leads 2 cancer trials in OnCo, testing the BCR-ABL inhibitor radotinib (Supect) in chronic myeloid leukaemia.","summary":"Il-Yang Pharmaceutical is a South Korean pharmaceutical manufacturer founded in 1946 that produces prescription and over-the-counter medicines, influenza vaccines and health products. Its in-house new drugs include Noltec (ilaprazole) and Supect (radotinib), a BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukaemia. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo (2 in phase 3 or 2/3): NCT03459534 (phase 3, A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failur...) and NCT03722420 (phase 3, Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.ilyang.co.kr"},{"label":"ClinicalTrials.gov: trials led by Il-Yang Pharmaceutical","url":"https://clinicaltrials.gov/search?lead=Il-Yang%20Pharm.%20Co.%2C%20Ltd."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib","radotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03459534","nct03722420"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Yongin","country":"KR","companyType":"pharma","website":"https://www.ilyang.co.kr","ticker":"KRX:007570","founded":1946,"stage":"public","investors":[],"funding":[]},"route":"/companies/il-yang-pharmaceutical/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"radotinib","kind":"drug","name":"Radotinib","route":"/drugs/radotinib/"}],"trial":[{"id":"nct03459534","kind":"trial","name":"A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs","route":"/trials/nct03459534/"},{"id":"nct03722420","kind":"trial","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","route":"/trials/nct03722420/"}]}}